Sponsors (48)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Introduced April 9, 2025 by Brian K. Fitzpatrick · Last progress April 9, 2025
Strengthens federal support for brain tumor research, clinical trials, biomarker testing, and survivor care by requiring transparency for NIH-funded brain tumor biospecimen collections; creating and funding new NIH research award programs for glioblastoma therapeutics and brain tumor cellular immunotherapies; launching a national awareness campaign and demonstration grants for clinical trials and biomarker testing; funding pilot programs to improve survivorship care; and directing the FDA to issue guidance within one year to reduce exclusion of brain tumor patients from clinical trials. The bill sets reporting deadlines for existing and new NIH-funded biospecimen collections, authorizes multiyear funding levels for specific research and outreach programs for fiscal years 2026–2030, and gives NIH enforcement authority for repeated reporting violations.
The bill channels targeted federal funding and programs to accelerate brain‑tumor research, trial access, and survivorship care—improving options for patients and researchers—while raising taxpayer costs, adding administrative burdens, and creating equity, privacy, and safety risks if safeguards and funding distribution are not carefully managed.
People with brain tumors (patients and families) will see expanded, sustained federal investment and programs to accelerate development of new treatments, diagnostics, and early‑phase trials.
Patients (including those in underserved communities) will gain better access to clinical trials through outreach, enrollment assistance, clearer eligibility guidance, and efforts to make trials more discoverable.
Researchers and institutions will have improved discoverability and standardized metadata for NIH-funded brain tumor biospecimens, making it easier to share samples, reproduce results, and collaborate.
American taxpayers will face increased federal spending (multiple new appropriations and authorizations across the bill), which could add to budgetary pressure or crowd out other priorities.
Broader trial eligibility and trial enrollment of vulnerable patients without strict safeguards could raise safety risks for some participants.
Researchers, hospitals, and smaller institutions will face administrative burdens and reporting requirements (with possible funding penalties), diverting time from research and risking disruption of projects or employment.